Clinical trials: Hematologic Disorders
Precursor Cell Lymphoblastic Leukemia-Lymphoma
InO - A Retrospective Study of UK Patients With Leukaemia
The purpose of this study is to describe the demographics and clinical characteristics, treatment pathway, and effectiveness and safety of inotuzumab ozogamicin in patients with relapsed/refractory B-cell acute lymphoblastic…
- Trial name
- InO (NCT04456959)
- Testing
- Inotuzumab Ozogamicin
- Where
- 4 sites in United Kingdom
- Volunteers
- 28 people
- Sponsor
- Pfizer
Anemia
Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients
This is a double-blind, randomized, multicenter, parallel-group, equivalence study involving about 462 clinically stable hemodialysis patients aged 18 years or above suffering from anemia and treated previously with a stable dose…
- Trial name
- NCT00666835
- Testing
- HX575 epoetin alfa Hexal AG, ERYPO®, Janssen-Cilag
- Where
- 54 sites in Austria, Germany
- Volunteers
- 478 people
- Sponsor
- Sandoz
Sickle Cell Disease
Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function
Background: Sickle cell disease (SCD) is a genetic disorder where red blood cells, that carry oxygen, are stiff and become stuck in small blood vessels.
- Trial name
- NCT06145282
- Testing
- Briquilimab, Filgrastim, Abatacept
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Study AG120-C-009 is a global, Phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of AG-120 (ivosidenib) + azacitidine vs placebo + azacitidine in adult…
- Conditions
- Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
- Trial name
- AGILE (NCT03173248)
- Testing
- AG-120, Azacitidine
- Where
- 90 sites in United States, Australia and 18 more
- Volunteers
- 146 people
- Sponsor
- Institut de Recherches Internationales Servier
Eosinophilic Esophagitis
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538.
- Trial name
- NCT04991935
- Testing
- CC-93538
- Where
- 167 sites in United States, Argentina and 13 more
- Volunteers
- 367 people
- Sponsor
- Celgene
Anemia
Study to Assess Feasibility and Safety of Iron Repletion With Feraheme in Iron Deficient Patients With Durable Ventricular Assist Device Support
Ferumoxytol injection (Feraheme®) is a parenteral form of iron supplementation that is FDA-approved for treatment of iron deficiency anemia.
- Trial name
- AMAGFeraheme (NCT04080908)
- Testing
- Ferumoxytol injection
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- NYU Langone Health
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
This phase II trial studies how well giving treosulfan together with fludarabine phosphate and total-body irradiation (TBI) works in treating patients with hematological cancer who are undergoing umbilical cord blood transplant…
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Blasts Under 5 Percent of Bone Marrow Nucleated Cells
- Trial name
- NCT00796068
- Testing
- Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
This is research study to find out if a drug called ADCT-301 is safe and to look at how patients respond to the study drug after an allogeneic transplantation.
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasm (MDS/MPN)
- Trial name
- NCT04639024
- Testing
- ADCT-301
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gwynn Long, M.D.
Purpura, Thrombotic Thrombocytopenic
IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients
The main purpose of this study is to evaluate safety and tolerability in patients diagnosed with asymptomatic antibody-mediated TTP with low ADAMTS13 activity after receiving single intravenous dose of IdeS.
- Trial name
- NCT02854059
- Testing
- IdeS (0.25 mg/kg), IdeS (0.50 mg/kg)
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- Hansa Biopharma AB
Fanconi Anemia
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100
The purpose of this research study is to determine whether an experimental drug called AMD3100 used in combination with another medication called G-CSF is safe and can help to increase the amount of blood stem cells (called CD34+…
- Trial name
- NCT00479115
- Testing
- AMD3100, AmCell CliniMACs
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Myelodysplastic Syndromes
Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents
The purpose of this study is to determine the proportion of confirmed responses (complete response, partial response, and hematologic improvement as defined by revised IWG criteria during the 12 months of treatment.
- Trial name
- NCT01246076
- Testing
- Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Refractory Plasma Cell Myeloma
Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
This phase II trial studies how well giving bortezomib, lenalidomide, and dexamethasone together works in treating patients with multiple myeloma undergoing stem cell transplant.
- Trial name
- NCT02353468
- Testing
- Bortezomib, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Colorado, Denver
Lymphocytic Leukemia, Chronic
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
This open-label, multicenter, randomized Phase III study is designed to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab + chlorambucil in participants with chronic…
- Trial name
- NCT02242942
- Testing
- Chlorambucil, Venetoclax, Obinutuzumab
- Where
- 122 sites in United States, Argentina and 19 more
- Volunteers
- 445 people
- Sponsor
- Hoffmann-La Roche
Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
This phase II trial investigates whether patients greater than or equal to 65 years of age diagnosed with myeloma or another plasma cell malignancy will have better outcomes with transplant followed by maintenance therapy, as…
- Conditions
- Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Primary Systemic Amyloidosis
- Trial name
- NCT01849783
- Testing
- dexamethasone, cisplatin, doxorubicin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Margarida Magalhaes-Silverman
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439175
- Testing
- Taselisib
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- Bu Flu TBI (NCT00245037)
- Testing
- therapeutic allogeneic lymphocytes, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- OHSU Knight Cancer Institute
Severe Hemophilia A
Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A
The purpose of this study is to obtain additional data on the safety and efficacy of Wilate in PTPs with hemophilia A with at least 150 previous exposure days (EDs) to a FVIII concentrate who undergo prophylactic treatment with…
- Trial name
- NCT02954575
- Testing
- Wilate
- Where
- 7 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 57 people
- Sponsor
- Octapharma
Immune Thrombocytopenic Purpura (ITP)
A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP
The purpose of this trial was to assess the ability of eltrombopag to induce sustained treatment-free remission in immune thrombocytopenia purpura (ITP) subjects who relapsed or failed to respond to an initial treatment with…
- Trial name
- TAPER (NCT03524612)
- Testing
- eltrombopag
- Where
- 32 sites in United States, Austria and 13 more
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens
This is a phase 2, multicenter, open label, nonrandomized study for patients with MM who will receive treatment with a SC bortezomib-containing combination regimen that does not contain thalidomide or vincristine.
- Trial name
- NCT01695330
- Testing
- Subcutaneous bortezomib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Oncotherapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.